Literature DB >> 23273528

Frequency, patient characteristics, treatment strategies, and resource usage of atrial fibrillation (from the Italian Survey of Atrial Fibrillation Management [ISAF] study).

Massimo Zoni-Berisso1, Alessandro Filippi, Maurizio Landolina, Ovidio Brignoli, Gaetano D'Ambrosio, Giampiero Maglia, Massimo Grimaldi, Giuliano Ermini.   

Abstract

Atrial fibrillation (AF) is 1 of the most important healthcare issues and an important cause of healthcare expenditure. AF care requires specific arrhythmologic skills and complex treatment. Therefore, it is crucial to know its real affect on healthcare systems to allocate resources and detect areas for improving the standards of care. The present nationwide, retrospective, observational study involved 233 general practitioners. Each general practitioner completed an electronic questionnaire to provide information on the clinical profile, treatment strategies, and resources consumed to care for their patients with AF. Of the 295,906 patients screened, representative of the Italian population, 6,036 (2.04%) had AF: 20.2% paroxysmal, 24.3% persistent, and 55.5% permanent AF. AF occurred in 0.16% of patients aged 16 to 50 years, 9.0% of those aged 76 to 85 years, and 10.7% of those aged ≥85 years. AF was symptomatic despite therapy in 74.6% of patients and was associated with heart disease in 75%. Among the patients with AF, 24.8% had heart failure, 26.8% renal failure, 18% stroke/transient ischemic attack, and 29.3% had ≥3 co-morbidities. The rate control treatment strategy was pursued in 55%. Of the 6,036 patients with AF, 46% received anticoagulants. The success rate of catheter ablation of the AF substrate was 50%. In conclusion, in our study, the frequency of AF was 2 times greater than previously reported (approximately 0.90%), rate control was the most pursued treatment strategy, anticoagulants were still underused, and the success rate of AF ablation was lower than reported by referral centers.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23273528     DOI: 10.1016/j.amjcard.2012.11.026

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  17 in total

1.  The involvement of pharmacies in the screening of undiagnosed atrial fibrillation.

Authors:  Pietro Amedeo Modesti; Gianni Donigaglia; Plinio Fabiani; Nicola Mumoli; Andrea Colella; Maria Boddi
Journal:  Intern Emerg Med       Date:  2017-09-19       Impact factor: 3.397

2.  Stereotactic Radiotherapy Ablation and Atrial Fibrillation: Technical Issues and Clinical Expectations Derived From a Systematic Review.

Authors:  Jessica Franzetti; Stefania Volpe; Valentina Catto; Edoardo Conte; Consiglia Piccolo; Matteo Pepa; Gaia Piperno; Anna Maria Camarda; Federica Cattani; Daniele Andreini; Claudio Tondo; Barbara Alicja Jereczek-Fossa; Corrado Carbucicchio
Journal:  Front Cardiovasc Med       Date:  2022-05-03

Review 3.  Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation.

Authors:  A John Camm; Fausto J Pinto; Graeme J Hankey; Felicita Andreotti; F D Richard Hobbs
Journal:  Europace       Date:  2015-07       Impact factor: 5.214

4.  Catheter Ablation of Atrial Fibrillation in U.S. Community Practice--Results From Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).

Authors:  Fredrik Holmqvist; DaJuanicia Simon; Benjamin A Steinberg; Seok Jae Hong; Peter R Kowey; James A Reiffel; Gerald V Naccarelli; Paul Chang; Bernard J Gersh; Eric D Peterson; Jonathan P Piccini
Journal:  J Am Heart Assoc       Date:  2015-05-21       Impact factor: 5.501

Review 5.  Atrial fibrillation management in older heart failure patients: a complex clinical problem.

Authors:  Giovanni Pulignano; Donatella Del Sindaco; Maria Denitza Tinti; Stefano Tolone; Giovanni Minardi; Antonio Lax; Massimo Uguccioni
Journal:  Heart Int       Date:  2016-09-22

6.  Antithrombotic prophylaxis of atrial fibrillation in an Italian real-world setting: a retrospective study.

Authors:  Giuliano Ermini; Valentina Perrone; Chiara Veronesi; Luca Degli Esposti; Giuseppe Di Pasquale
Journal:  Vasc Health Risk Manag       Date:  2017-07-05

7.  Connexin 43 is involved in the sympathetic atrial fibrillation in canine and canine atrial myocytes.

Authors:  Chenglin Shu; Weiqiang Huang; Zhiyu Zeng; Yan He; Beibei Luo; Hao Liu; Jinyi Li; Jian Xu
Journal:  Anatol J Cardiol       Date:  2017-05-24       Impact factor: 1.596

8.  Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF).

Authors:  Paulus Kirchhof; Bettina Ammentorp; Harald Darius; Raffaele De Caterina; Jean-Yves Le Heuzey; Richard John Schilling; Josef Schmitt; Jose Luis Zamorano
Journal:  Europace       Date:  2013-10-01       Impact factor: 5.214

Review 9.  Epidemiology of atrial fibrillation: European perspective.

Authors:  Massimo Zoni-Berisso; Fabrizio Lercari; Tiziana Carazza; Stefano Domenicucci
Journal:  Clin Epidemiol       Date:  2014-06-16       Impact factor: 4.790

10.  Opportunistic screening of atrial fibrillation by automatic blood pressure measurement in the community.

Authors:  Stefano Omboni; Willem J Verberk
Journal:  BMJ Open       Date:  2016-04-12       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.